P41 EB028239/EB/NIBIB NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2018	3
2019	3
2020	18
2021	15
2022	14
2023	13
2024	1

1

An engineered IL-2 partial agonist promotes CD8⁺ T cell stemness.

Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, Zhuang X, Mitra S, Lin JX, Gattinoni L, Powell JD, Restifo NP, Garcia KC, Leonard WJ. Mo F, et al. Nature. 2021 Sep;597(7877):544-548. doi: 10.1038/s41586-021-03861-0. Epub 2021 Sep 15. Nature. 2021. PMID: 34526724 Free PMC article.

2

Immunoengineering has arrived.

Green JJ. Green JJ. J Biomed Mater Res A. 2021 Apr;109(4):397-403. doi: 10.1002/jbm.a.37041. Epub 2020 Aug 4. J Biomed Mater Res A. 2021. PMID: 32588490 Free PMC article. Review.

3

Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.

Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH, Englert JM, Arwood ML, Wen J, Chan-Li Y, Tenora L, Majer P, Rais R, Slusher BS, Horton MR, Powell JD. Oh MH, et al. J Clin Invest. 2020 Jul 1;130(7):3865-3884. doi: 10.1172/JCI131859. J Clin Invest. 2020. PMID: 32324593 Free PMC article.

4

Toward Gene Transfer Nanoparticles as Therapeutics.

Kavanagh EW, Green JJ. Kavanagh EW, et al. Adv Healthc Mater. 2022 Apr;11(7):e2102145. doi: 10.1002/adhm.202102145. Epub 2022 Jan 17. Adv Healthc Mater. 2022. PMID: 35006646 Review.

5

Gene delivery for immunoengineering.

Neshat SY, Tzeng SY, Green JJ. Neshat SY, et al. Curr Opin Biotechnol. 2020 Dec;66:1-10. doi: 10.1016/j.copbio.2020.05.008. Epub 2020 Jun 15. Curr Opin Biotechnol. 2020. PMID: 32554325 Free PMC article. Review.

6

Approaches towards biomaterial-mediated gene editing for cancer immunotherapy.

Shannon SR, Ben-Akiva E, Green JJ. Shannon SR, et al. Biomater Sci. 2022 Nov 22;10(23):6675-6687. doi: 10.1039/d2bm00806h. Biomater Sci. 2022. PMID: 35858470 Free PMC article. Review.

7

Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.

Lopez-Bertoni H, Johnson A, Rui Y, Lal B, Sall S, Malloy M, Coulter JB, Lugo-Fagundo M, Shudir S, Khela H, Caputo C, Green JJ, Laterra J. Lopez-Bertoni H, et al. Signal Transduct Target Ther. 2022 Feb 9;7(1):37. doi: 10.1038/s41392-021-00857-0. Signal Transduct Target Ther. 2022. PMID: 35136034 Free PMC article.

8

Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.

Isser A, Livingston NK, Schneck JP. Isser A, et al. Biomaterials. 2021 Jan;268:120584. doi: 10.1016/j.biomaterials.2020.120584. Epub 2020 Dec 5. Biomaterials. 2021. PMID: 33338931 Free PMC article. Review.

9

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning.

McCurdy SR, Radojcic V, Tsai HL, Vulic A, Thompson E, Ivcevic S, Kanakry CG, Powell JD, Lohman B, Adom D, Paczesny S, Cooke KR, Jones RJ, Varadhan R, Symons HJ, Luznik L. McCurdy SR, et al. Blood. 2022 Jan 27;139(4):608-623. doi: 10.1182/blood.2021013054. Blood. 2022. PMID: 34657151 Free PMC article. Clinical Trial.

10

Safety considerations for nanoparticle gene delivery in pediatric brain tumors.

Luly KM, Choi J, Rui Y, Green JJ, Jackson EM. Luly KM, et al. Nanomedicine (Lond). 2020 Aug;15(18):1805-1815. doi: 10.2217/nnm-2020-0110. Epub 2020 Jul 23. Nanomedicine (Lond). 2020. PMID: 32698671 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

61 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year